3 things that could affect the GSK share price in 2022
The GSK share price is up in 2022. Roland Head has been taking a look at what could be in store for shareholders as the year unfolds.
Source: fool.co.uk
📰 Hal Barron News
Page 12 - Hal Barron News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hal Barron. Real-time updates on events, politics, business and more.
Big questions for Unilever board after GSK pursuit ends
Delivering a minor heart attack to the share price, however temporarily, is not a good look
Source: theguardian.com
ALEX BRUMMER: GSK loses its biggest fish - can boss Walmsley survive?
Emma Walmsley could not have done more to woo Hal Barron to Glaxo. He was offered a pay package worth more than that of the chief executive.
Source: thisismoney.co.uk
GSK's top scientist quits to join Jeff Bezos-backed anti-aging start-up Altos Labs
In a setback for chief exec Emma Walmsley, veteran drug developer Hal Barron (pictured) will step down as chief scientific officer in August.
Source: thisismoney.co.uk
Top 10 stories of 2021
COVID was once again the top story of the year in Monroe County.
Lake Erie United States Flat Rock Oxford High School Monroe High School Monroe County Community College
Source: monroenews.com
Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Xevudy approved in Europe to treat COVID-19
Investegate announcements from GlaxoSmithKline PLC, Xevudy approved in Europe to treat COVID-19
Source: investegate.co.uk
According to new data, GSK-VIR drug works against all omicron mutations
GSK said that its COVID-19 antibody-based therapy is effective against all mutations of the new Omicron coronavirus strain.
Source: dailytimes.com.pk
Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Sotrovimab retains its activity vs Omicron variant
Investegate announcements from GlaxoSmithKline PLC, Sotrovimab retains its activity vs Omicron variant
Source: investegate.co.uk
New data shows GSK-Vir drug works against all Omicron mutations
British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
United Kingdom Sherry Jacob Phillips Pushkala Aripaka Hal Barron Thomson Reuters Trust Principles Vir Biotechnology
Source: reuters.com